Peregrine Pharmaceuticals (NASDAQ: CDMO) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Peregrine Pharmaceuticals to related companies based on the strength of its profitability, earnings, analyst recommendations, risk, dividends, valuation and institutional ownership.
Volatility and Risk
Peregrine Pharmaceuticals has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500. Comparatively, Peregrine Pharmaceuticals’ peers have a beta of 1.12, meaning that their average stock price is 12% more volatile than the S&P 500.
This table compares Peregrine Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Peregrine Pharmaceuticals||$57.63 million||-$28.15 million||-4.57|
|Peregrine Pharmaceuticals Competitors||$614.64 million||$60.23 million||69.24|
Peregrine Pharmaceuticals’ peers have higher revenue and earnings than Peregrine Pharmaceuticals. Peregrine Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings for Peregrine Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Peregrine Pharmaceuticals Competitors||170||842||1849||61||2.62|
Peregrine Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 212.50%. As a group, “Biopharmaceuticals” companies have a potential upside of 4.99%. Given Peregrine Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Peregrine Pharmaceuticals is more favorable than its peers.
This table compares Peregrine Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Peregrine Pharmaceuticals Competitors||-13,490.70%||-54.20%||-24.72%|
Institutional & Insider Ownership
18.4% of Peregrine Pharmaceuticals shares are held by institutional investors. Comparatively, 43.4% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 2.5% of Peregrine Pharmaceuticals shares are held by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Peregrine Pharmaceuticals peers beat Peregrine Pharmaceuticals on 7 of the 13 factors compared.
About Peregrine Pharmaceuticals
Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., incorporated on September 25, 1996, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.
Receive News & Ratings for Peregrine Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.